课题基金 / 基金详情

DEVELOPEMENT OF RADIOIODINATED RADIOPHARMACEUTICALS FOR INTERNAL RADIATION THERAPY OF TUMOR BASED ON ITS SPECIFIC METABOLIC ACTIVITY

DEVELOPEMENT OF RADIOIODINATED RADIOPHARMACEUTICALS FOR INTERNAL RADIATION THERAPY OF TUMOR BASED ON ITS SPECIFIC METABOLIC ACTIVITY
基于肿瘤特异性代谢活性的用于肿瘤内放射治疗的放射性碘化放射性药物的开发
批准号:
12557076
负责人:
KAWAI Keiichi
金额:
$4.35万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

KAWAI Keiichi的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of this study is to develop a new radiopharmaceutical labeled with radioiodine for detection and therapy of tumors, which has affinity to a characteristic metabolism in tumor. 3-Iodo-4-hydroxyphenyl-L-cysteine (I-L-PC), as we have reported previously, was found to have an interaction for tyrosinase, an essential and rate-limiting enzyme to melanin biosynthesis. In this study, considering higher affinity for tyrosinase, we synthesized 3-iodo-4-hydroxyphenylcysteamine (I-PCA) that was an amine derivative of I-L-PC and examined biodistribution study in melanoma-bearing mice.4-Hydroxyphenylcysteamine (4-PCA) was synthesized and radioiodinated in our laboratory. I-PCA was prepared by conventional chloramine-T method under no-carrier added condition. The biodistribution of I-PCA in B16 melanoma-bearing C57BL6 mice showed rapid blood clearance, renal excretion and low accumulation in normal tissue. The results suggested that I-PCA achieved the desired affinity for melanin formation. T … More hat is, I-PCA has high potentiality for diagnosis of malignant melanoma. Moreover, because I-PCA accumulated low in normal tissue and showed rapid clearance, it might be applied as a therapeutic radiopharmaceutical when labeled with I-131.Approximately 70 % of I-IMP, a cerebral blood flow agent, is bound to serum protein. If the binding of radiopharmaceutical to serum protein can be inhibited by displacers with high protein binding affinity, the total clearance and tissue distribution of this tracer would be enhanced. The interaction between I-IMP and several binding displacers was evaluated to improve cerebral imaging. The free fraction rate of I-IMP was increased up to 1.2 times of control with 6MNA, a clinically available HSA site II displacer. In monkey scintigraphic study, cerebral accumulation was significantly accelerated. Indeed, 6MNA treatment increased free I-IMP in monkey serum. Since the displacement method could easily be applied to human study, the competitive displacement can control tissue distribution and kinetics of radiopharmaceuticals in clinical application. Less
期刊论文(120)
专著(0)
科研奖励(0)
会议论文
Akizawa H., Arano Y: "Novel methods of altering pharmacokinetics in radiopharmaceutical design : metabolizable linkers and pharmacokinetics"Q. J. Nucl. Med.. 46. 206-223 (2002)
Akizawa H.、Arano Y:“放射性药物设计中改变药代动力学的新方法:可代谢连接体和药代动力学”Q。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishii R., Kawai K., Nagamachi S., Arano Y., et al.: "A Novel Radiopharmaceutical for Detection of Malignant Melanoma Based on Melanin Formation : 3-Iodo-4-hydroxyphenyl-Lーcystein"Nucl. Med. Commun.. 24. 575-582 (2003)
Nishii R.、Kawai K.、Nagamachi S.、Arano Y. 等人:“一种基于黑色素形成检测恶性黑色素瘤的新型放射性药物:3-碘-4-羟基苯基-半胱氨酸”Nucl Med。 . 24. 575-582 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Uehara T., Fujioka Y., Saji H., Arano Y.: "Approaches to Reduce Renal Radioactivity Levels of Antibody Fragments."Biomed. Res. Trace Elements. 12. 152-158 (2001)
Uehara T.、Fujioka Y.、Saji H.、Arano Y.:“降低抗体片段肾脏放射性水平的方法”。Biomed。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kawai K. Takamura H., Nishii R., Jinnouchi S., Nagamachi S., Tamura S., Arimori K., Otagiri M.: "Competitive Displacement of Serum Protein Binding to Regulate Pharmacokinetics."In Serum Albumin and α_1-Acid Glycoprotein from Basic Sciences to Clinical App
Kawai K. Takamura H.、Nishii R.、Jinnouchi S.、Nagamachi S.、Tamura S.、Arimori K.、Otagiri M.:“血清蛋白结合的竞争性置换以调节药代动力学。”血清白蛋白和 α_1-酸糖蛋白从基础科学到临床应用
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
59
    Development strategy of tumor diagnostic agent by system upregulated functional biomolecule based on expression analysis of tumor associated transporter
    • 批准号:
      15K15452
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.25万
    • 财政年份:
      2015
    • 负责人:
      KAWAI Keiichi
    • 依托单位:
    Development of a molecular targeted radiolabeled diagnostic agent useful for personalized drug therapy of psychoneurotic diseases
    • 批准号:
      25293260
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.65万
    • 财政年份:
      2013
    • 负责人:
      KAWAI Keiichi
    • 依托单位:
    The design strategy for tumor diagnostic agents utilizing the functional biomolecule expression system based on gene expression analysis of tumor cells
    • 批准号:
      24659558
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2012
    • 负责人:
      KAWAI Keiichi
    • 依托单位:
    The probe design strategy of post-FDG tumor diagnostic agents based on the functional biomolecule expression analysis of human cultured cells
    • 批准号:
      21659286
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.09万
    • 财政年份:
      2009
    • 负责人:
      KAWAI Keiichi
    • 依托单位: